London--(Marketwire - December 11, 2007) -

        Curidium Medica plc ("Curidium" or the "Company")

 Curidium Announces Strategic Partnership with Takeda Research Investment, Inc.

               - Investment Focus on Major Depressive Disorder -

LONDON, UK, 5th December 2007, Curidium Medica plc, (LSE:CUR), a personalized
medicine company focused on bringing the right drug to the right patient,
announced today that it has entered into a strategic partnership with Takeda
Research Investment, Inc. (TRI), the corporate investment arm of Takeda
Pharmaceutical Company, Limited.  As part of the agreement TRI will purchase
10,491,803 ordinary shares and warrants for 20 million additional ordinary
shares in the Company.  The Company will use the proceeds to initiate research,
using its proprietary platform Homomatrix(R), to identify potential patient
subgroups within Major Depressive Disorder characterized by unique gene
expression profiles and specific drug targets. The warrant exercise is dependent
on completion of the research program and future licensing.  In addition, TRI
and Curidium have entered into a license option agreement whereby Takeda
Pharmaceutical Company Limited, through TRI, receives an option right to select
Major Depressive Disorder biomarker and drug target discoveries made by Curidium
and to negotiate a license to the intellectual property rights in those assets.
Financial terms for the license are expected to include upfront payments,
milestones and royalties on product sales.

"This investment by TRI reflects a confidence in our approach to personalized
medicine and allows Curidium to collaborate with the leading Japanese
pharmaceutical company intent on expanding its significant global presence",
stated Gosse B. Bruinsma, MD, Curidium's Executive Chairman.  "We are looking
forward to collaborating with Takeda and delivering on this important research

"We are delighted to have this opportunity to work with Curidium and are
encouraged by their personalized medicines advances and approach to major
depression," commented Dr. Graeme Martin, TRI's President & CEO.  "This
indication is a key strategic focus for Takeda and we expect that reliable
methods for patient stratification will bring significant therapeutic benefits
in this area of exceptional medical need."

Major Depressive Disorder is one of the most prevalent psychiatric illnesses in
the United States, estimated to affect over 20 million adults in the US alone.
Depression is also the leading cause of disability worldwide. As observed in the
landmark STAR*D trial, only 25 - 40% of depressed patients are able to achieve
clinical remission with the most commonly used anti-depressive agents.  By
identifying markers for subpopulations of patients with depression, Curidium
believes that tailoring treatment to patient types may be possible.

The 10,491,803 new ordinary shares represent 1.85% of the enlarged share capital
of the Company.  Application for admission of the new ordinary shares to trading
on AIM is expected to occur on 11th December 2007. Following admission of the
new ordinary shares the Company will have 568,303,195 ordinary shares in issue.

The new ordinary shares and warrants have been issued for a total initial
payment of one million two hundred and fifty thousand pounds (£1,250,000).  The
10,491,803 new ordinary shares have an issue price of 3.813p representing the
average of the Company's closing share price in the last 10 days of trading.
The warrants for the purchase of 20 million ordinary shares shall be at a price
ranging from par value (0.1 pence) in the event of a non-delivery by Curidium of
a final report within 22 months of the execution of the agreement to one hundred
and fifty percent (150%) of the issue price should Takeda choose not to license
intellectual property resulting from the research program.

                                    - Ends -

For further information, please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Executive Chairman, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0) 20 7831 3113
Financial Dynamics

About Curidium Medica plc (Curidium)

Curidium is a personalized medicine company developing companion diagnostics and
targeted medicines to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted
in the identification of a blood diagnostic test, PsychINDxTM, which classifies
patients with schizophrenia/bipolar disorder into four subgroups. PsychINDxTM
may have the potential to improve the treatment of patients with schizophrenia/
bipolar disorder.

Many chronic human diseases are heterogeneous with patient populations
consisting of mixed subgroups. Through the use of its proprietary analysis tool,
Homomatrix(R), Curidium aims to reveal different patient subgroups characterized
by distinct underlying disease mechanisms potentially leading to the
identification of:

1).  Diagnostics for better identification and treatment within heterogeneous 
     disease populations.

2).  Improved therapies identified through novel drug targets.

3).  Personalized medicines using companion diagnostics and targeted treatments.

Curidium intends to continue to use this approach to improve patient treatments
in a variety of therapeutic areas. Further information on Curidium can be found
at the Company's website:

About Takeda Research Investment, Inc. (TRI)

Located in Palo Alto, California, Takeda Research Investment, Inc. (TRI) is a
wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TPC), the
largest pharmaceutical company in Japan. TRI's mission is to identify, help
create and support the development of new therapeutic drug discovery
opportunities worldwide as a strategic investor on behalf of TPC. The primary
focus of TRI is on medium- and long-term returns in the form of products and
technologies for Takeda group. Takeda is committed to striving toward better
health for individuals and progress in medicine by developing superior
pharmaceutical products. To learn more about the company, visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange